TRIAMCINOLONE ACETONIDE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
| Metabolism | Primarily hepatic; metabolized by CYP3A4 to inactive metabolites. |
| Excretion | Renal (primarily as metabolites, <5% unchanged); biliary/fecal (minor). |
| Half-life | Terminal elimination half-life approximately 2-5 hours; but suppression of adrenal function (HPA axis) can persist for 7-30 days depending on dose and duration. |
| Protein binding | 68-71% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Approximately 1.4 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Intranasal: ~50%; Inhaled: ~25% (deposition and absorption dependent); Oral: ~23% (first-pass metabolism); Topical: low systemic absorption (depends on site, occlusion). |
| Onset of Action | Intra-articular: 24-72 hours; Topical: varies by formulation (hours to days); Inhalation: 24-48 hours for asthma control. |
| Duration of Action | Intra-articular: 1-4 weeks after single injection; Topical: varies by vehicle and site; Inhalation: 12-24 hours for bronchodilator effect. |
| Molecular Weight | 434.5 |
Intramuscular: 40-80 mg every 4 weeks. Intra-articular: 5-40 mg depending on joint size. Topical: Apply thin film to affected area 2-4 times daily.
| Dosage form | OINTMENT |
| Renal impairment | No adjustment required for any GFR level. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment (Child-Pugh C) due to potential for increased systemic exposure. |
| Pediatric use | Intramuscular: 0.03-0.2 mg/kg every 4 weeks (max 40 mg). Topical: Apply sparingly; avoid prolonged use. |
| Geriatric use | Use lowest effective dose; monitor for hyperglycemia, hypertension, and osteoporosis with prolonged use. |
| 1st trimester | Use only if potential benefit justifies potential risk to fetus. Corticosteroids are associated with increased risk of cleft palate at doses >10 mg/day. Avoid high doses. |
| 2nd trimester | Use only if clearly needed. Monitor for fetal growth restriction with prolonged use. May increase risk of preterm delivery. |
| 3rd trimester | Use only if clearly needed. Prolonged use may cause fetal adrenal suppression. Avoid high doses near term. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Triamcinolone acetonide crosses the placenta. The degree of transfer is variable but significant systemic exposure can occur. |
■ FDA Black Box Warning
None
| Common Effects | Hyperglycemia |
| Serious Effects |
Systemic fungal infectionsHypersensitivity to triamcinolone or any component
| Precautions | Immunosuppression and increased susceptibility to infections, HPA axis suppression with prolonged use, Osteoporosis with long-term use, Cataracts and glaucoma with ocular use, Growth retardation in children |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit sodium intake to reduce fluid retention. Avoid alcohol as it may increase risk of gastrointestinal bleeding. |
Loading safety data…
| Breastfeeding |
| Triamcinolone acetonide is excreted into breast milk in low amounts. Use with caution, especially with high doses or prolonged therapy. Monitor infant for adrenal suppression. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of orofacial clefts (odds ratio ~1.3-3.4) based on observational studies. Second trimester: Possible growth restriction with chronic use. Third trimester: Risk of fetal hypothalamic-pituitary-adrenal suppression, transient neonatal adrenal insufficiency. Avoid high-dose systemic use. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal growth ultrasound if chronic use. Neonatal observation for adrenal suppression if maternal therapy continued until delivery. |
| Fertility Effects | No evidence of impaired fertility in humans; animal studies show dose-dependent effects at high doses. Reversible menstrual irregularities possible with chronic use. |
| Clinical Pearls | For intralesional use, limit dose to 1 mg per lesion to avoid atrophy. For intra-articular use, inject no more frequently than every 3-4 weeks to prevent cartilage damage. Avoid abrupt cessation after prolonged therapy to prevent adrenal insufficiency. Not for intravenous or ophthalmic use. Use with caution in patients with tuberculosis, ocular herpes simplex, or peptic ulcer disease. |
| Patient Advice | Do not stop taking this medication suddenly without consulting your doctor. · Report any signs of infection, such as fever or sore throat, or worsening of condition. · Avoid live vaccines during treatment. · May cause increased appetite, weight gain, or fluid retention. · Notify your doctor if you experience vision changes, easy bruising, or black/tarry stools. · Do not use more than prescribed; overuse can lead to serious side effects. |